Microplastics and Nanoplastics in Human Health: From Environmental Contaminants to Internal Pollutants—A Comprehensive Review of Exposure, Bioaccumulation, Toxicity Mechanisms, and Emerging Detection Technologies

The plastic pieces of synthetic polymers, which were previously regarded as primary pollutants of the environment, are increasingly being discovered as internal pollutants of the human body. This review provides a comprehensive overview of the available evidence on human exposure, tissue distribution, and associated biological effects of micro- and nanoplastics. Ingesting contaminated food and water is the major exposure pathway, with inhalation and dermal contact being secondary routes. Various organ systems have been identified as containing polymer particles through the use of advanced analytical methods, including blood, liver, lungs, placenta, breast milk, and brain tissue. Experimental animal studies suggest associations with tissue injury, metabolic illness, and neurotoxicity. Polyethylene, polypropylene, polystyrene, and polyethylene terephthalate are the most frequently found polymers in human samples. New clinical findings indicate potential health implications, though current human evidence remains largely associative rather than causal: a cardiovascular study observed more than a two-fold rise in mortality among patients with polymer-containing arterial plaques, and recent evidence demonstrates over-accumulation of polymers in brain tissue, raising questions about neuroinflammatory processes. Detection technologies have advanced substantially, with deep learning-based polymer classification achieving 95–99% accuracy and ultrasensitive electrochemical and surface plasmon resonance biosensors reaching detection limits approaching 10−11 M. Despite these advances, critical issues remain, including lack of standardized analytical procedures, absence of chronic exposure models for humans, and insufficient longitudinal epidemiological data. To address these gaps, physiologically relevant experimental systems including organoids and organ-on-chip platforms will be required, in addition to well-designed prospective cohort studies.